MENTOR SALINE BREAST IMPLANT PMA WILL BE READY IN AUGUST 1995
This article was originally published in The Gray Sheet
Executive Summary
MENTOR SALINE BREAST IMPLANT PMA WILL BE READY IN AUGUST 1995 for use of the device in breast augmentation, the company said June 2 at an FDA public hearing. Mentor is envisioning submission of a premarket approval application that includes one-year follow- up data in augmentation patients with collection of two- and three-year follow-up data after the implant is approved. FDA called the hearing to gain input on the timing of a call for PMAs on saline breast implants, which could affect the continued availability of the devices ("The Gray Sheet" May 9, p. 17). The agency issued a proposed call in January 1993 for the preamendment Class III products. After the agency finalizes the call, manufacturers will have 90 days in which to submit PMAs. The companies can continue marketing their products while their PMAs are under review.
You may also be interested in...
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.
Helping Organizations Deliver On KPIs And Giving Staff A Voice
ImproveWell has won awards for its software technology that allows health care staff at the sharp end of patient care to report on problems as they happen. The outcome is a real-time learning process that contributes to improved operational efficiencies for health systems, says In Vivo Rising Leader Lara Mott.
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.